Responses of patients with juvenile idiopathic arthritis to methotrexate: a genomic outlook
| Autor: | Gabriele Stocco, Andrea Taddio, Marianna Lucafò, Davide Selvestrel, Serena Pastore, Letizia Pugnetti, Sofia Pagarin, Valentina Moressa, Giuliana Decorti |
|---|---|
| Přispěvatelé: | Selvestrel, D., Lucafo, M., Pugnetti, L., Pagarin, S., Moressa, V., Pastore, S., Taddio, A., Stocco, G., Decorti, G. |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
musculoskeletal diseases
juvenile idiopathic arthritis Methotrexate pharmacoepigenetics pharmacogenetics serum biomarkers therapy personalization Immunology Arthritis Bioinformatics juvenile idiopathic arthriti immune system diseases pharmacoepigenetic Immunology and Allergy Medicine Juvenile Humans Epigenetics skin and connective tissue diseases Adverse effect Child business.industry Genomics medicine.disease Arthritis Juvenile Treatment Outcome Rheumatoid arthritis Pharmacogenomics Antirheumatic Agents serum biomarker pharmacogenetic business Pharmacogenetics medicine.drug |
| Popis: | Introduction Juvenile idiopathic arthritis (JIA) is a chronic disease characterized by persistent joint inflammation. JIA is the most common pediatric chronic rheumatic disease and no curative therapy is currently available. Methotrexate (MTX) is an important treatment for JIA even though a high inter-individual variability in response is observed in patients. Among the factors of this variability, genetics and epigenetics might play an important role. Areas covered This review summarizes the results of pharmacogenetic and pharmacoepigenetic studies regarding MTX response in JIA. Studies considering epigenetic factors in JIA patients are still very limited, therefore this review includes also studies performed in adult patients with rheumatoid arthritis. Moreover, the relevance of biomarkers measured in blood or urine of JIA patients in relation to MTX treatment is discussed. Expert opinion Nowadays, even though many pharmacogenomics studies have been published, a specific genetic marker predictor of MTX efficacy or adverse events has not yet been identified. Encouraging results are available and great expectations rely on the study of epigenetics. Future studies are needed in order to identify genetic and epigenetic biomarkers that can be implemented in the clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|